Houstonian fosters collaboration and mentorship for women in venture capital

HOUSTON INNOVATORS PODCAST EPISODE 46

Sandy Guitar — along with other Houston female venture capitalists — are gathering virtually to promote networking and friendship amid the pandemic. Photo courtesy of Sandy Guitar

When Sandy Guitar saw that Austin had a group of women in venture capital group that promoted collaboration and networking, she knew Houston had to have one too.

Guitar, who is the managing director of the HX Venture Fund, connected with the Austin group, picked their brains and asked for advice on starting a local iteration, and recruited a few fellow female VC experts in town — and the rest is history.

"There's a part of us as women that understands necessarily that work and life combine," Guitar says on this week's episode of the Houston Innovators Podcast. "Our lives as women don't allow us to segment our lives. The truth is those parts of our lives come together. The more we can do that, the more we can build networks that help us achieve everything we want both professionally and personally."

Now, over a year later, the Women Investing in VC in Houston group has grown to over 30 members — so much that their virtual visits are broken into smaller groups. The group boasts diversity and has representatives across types of funds. To join, women must simply live in Houston and be a venture capital investor. Other than that, the group is unstructured and casual, which fosters an environment where members are allowed to ask a stupid question or speak up on something personal, as Guitar says.

"When you have no dues and very little formality, no structure, no pressure to attend — it's in that setting that you actually build trust. Organically, the friendships come together," she says. "That's what it's really about."

While the group had pre-pandemic beginnings, the model of mentorship and networking is more relevant now than ever. Men and women alike, Guitar says, are not able to silo work and life as we work from home and practice social distancing.

"COVID has made us vulnerable in an entirely new set of ways," she says. "We use our support groups — whatever they are — to help us."

Guitar discusses the group and how what the venture capital industry needs to do to evolve into a more welcoming space for women in the episode of the podcast. You can listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


The Women Investing in VC in Houston group has pivoted to virtual events since the start of COVID-19. Photo courtesy of Sandy Guitar

HX Venture Fund recently hosted a virtual panel on how the tide has turned in Houston when it comes to tech investment. Getty Images

Overheard: Experts discuss why Houston is the next hub for tech investing

eavesdropping in Houston

When Joe Alapat, co-founder and CEO of Liongard, was first getting started on his company, he says a few people recommended he go to Austin or one of the coasts to give his software company a better chance.

"For me, the thought process never really entered my mind that Houston was a place where I would be challenged in doing what I do well. My network is here," Alapat shared on a virtual panel hosted by the HX Venture Fund.

Turns out, it was a good decision. Liongard recently closed a $17 million series B round led by Updata Partners, a portfolio fund of HXVF. Moderated by Brian Richards of Accenture's Houston innovation hub, the panel asked Alapat, Sandy Guitar of HXVF, and Carter Griffin of Updata why Houston is the next hub for tech investing. Here are some key moments from the discussion.

“We’re cautious when we go into places — like Austin and Boston — where there’s a lot of activity both on the company side and the investor side. We’d rather find the opportunities where things aren’t as competitive and frothy, and you’re really dealing with people trying to build a real business, serve customers, and build value in the right way, and not just catch lightning in a bottle and build the next unicorn.”

—says Griffin about Updata's strategy of looking at cities like Houston in the middle of the country.

“A lot has changed in the past couple of years — the thought process, the awareness, as well as the willingness for folks to think about Houston as a place where you can build a startup.”

— says Alapat about how Houston's startup ecosystem has evolved since he started Liongard in 2015. He later notes that Houston's innovation leaders have done well to not copy other metros, but listen and learn from the successes and mistakes of other innovation cities.

“There was this feeling that we needed to be uniquely Houston — we couldn’t replicate Silicon Valley or Austin, we needed to be us. But we were going to have to do things differently. We couldn’t keep doing the same things and expecting this [change.]”

— Richard says, noting the corporate mindset, among other aspects of the ecosystem, shifted to be more focused on startups.

“The VCs are very interested in engaging in this model. So, we’re spoiled for choices is one way of saying it.”

— Guitar says on interest from venture funds in HXVF, noting that the VCs see an opportunity for their portfolio startups to connect with HXVF's corporate partners.

The HX Venture Fund reached a proof point of its model — one that arrived much earlier than expected. Getty Images

Houston's fund of funds expands its portfolio and team after reaching benchmark with local investment

money moves

When a Houston software startup closed a $17 million series B funding round, it was a big win for more than just the startup. Not only was the deal among the few Houston venture capital deals to happen amid the COVID-19 outbreak, but it represented a proof of concept for Houston's fund of funds.

The HX Venture Fund was founded in October of 2018 to encourage investment into local startups by raising corporate funds and investing into a portfolio of non-Houston venture capital funds that show an interest in Houston. HXVF hit a milestone last month when Liongard, a software-as-a-service company based in Houston, closed its fundraising round led by Updata Partners — one of HXVF's portfolio funds.

To date, the HXVF has reviewed over 150 venture capital funds and invested in eight: Austin-based LiveOak Venture Partners and Next Coast Ventures, Washington D.C.-based Updata Partners, Chicago-based Baird Capital, San Francisco-based VenBio, and Boston-based .406 Ventures, OpenView Venture Partners, and Material Impact Fund. Since each investment, those funds have invested in over 30 startups that are also included in the greater HXVF portfolio.

These HXVF portfolio funds represent various stages — from seed to growth stages, like Liongard — and across industries, from software and hardware to life sciences — "the whole gamut," says Sandy Guitar, managing director of HXVF.

"What that means now is there is over $2 billion of venture capital that actively has Houston on its radar right now," Guitar tells InnovationMap.

The Liongard investment represents a proof point for the fund of funds — one that comes earlier than expected. HXVF invested in Updata less than six months before Liongard closed its round with Updata's lead investment. Guitar says she expected to get to this milestone within 18 to 24 months of the fund of funds deploying capital — and it's happened in just nine months.

"You have this trickle down effect, where it can easily take two to three years to get your capital at work," Guitar says, explaining that HXVF first has to raise funds from its corporate partners, then vet and invest in the VCs, and, finally, wait to see how those funds invest.

Of course, the pandemic has not exactly helped the growth of Houston's startup and venture capital sectors. While COVID-19 has allowed growth in some sectors — telemedicine, for instance — it has limited the opportunities for startups to test the market.

"To build great startups, a startup has to do what I call 'run into walls.' They have to test the market, get it wrong, and pivot. The problem right now is there are no walls to run into," Guitar says. "You have to have an actively running economy and market for proof points of what's working and what's not working."

Meanwhile, Guitar observes, VC investors have limited their activity to their own networks due to the inability to meet face-to-face with unfamiliar startups. Comparing the VC-startup relationship to a marriage, you wouldn't meet and marry someone you've never met in person just like investors wouldn't fund an entrepreneur they have only ever met via Zoom.

"A lot of VCs are staying in their known networks in the short term," says Guitar, while, in the long term, VCs are going to rely on introductions to entrepreneurs from their network.

With this benchmark secured, HXVF is continuing to grow its portfolio — as well as its team. Recently, Guitar — who runs the fund with Guillermo Borda — brought on Houston native Aleece Hobson as venture partner.

"Aleece joining is a phenomenal step for us — a dedicated resource and venture partner on activation," says Guitar on the hire. "I think it speaks to the seriousness of purpose we have to make this not just an investment platform, but one that moves the needle on Houston."

Guitar says HXVF is also growing its limited partners with the addition of Rice University, which joins the likes of HEB, Shell, Chevron, and Houston Methodist — to name a few.

"We're going to be getting even closer to our limited partners' needs and introducing them to the 34 portfolio companies," Guitar says "and creating meaningful collisions between those two groups."

Aleece Hobson joined the HX Venture Fund as venture partner. Photo courtesy of HXVF

Sandy Wallis, managing director of the HX Venture Fund, has seen investing in Houston change over her 20-year career. Courtesy of Sandy Wallis

HX Venture Fund leader talks investment trends in Houston and plans for 2020

HOUSTON INNOVATORS PODCAST EPISODE 13

After 20 years in the venture capital world, Sandy Guitar Wallis has seen the evolution of investing — on both coasts and here in Houston as well.

Now, as managing director of the HX Venture Fund, Wallis is playing the long game. The fund of funds acts as a broker to other venture funds, raising money from limited partners and then strategically doling out investments to non-Houston venture funds, with the hope that those funds circle back into the Houston innovation ecosystem with a multiplier effect.

"We have raised a fund of funds with the HX Venture Fund, and we're deploying that capital across probably 10 venture capital funds over time," Wallis explains on the most recent episode of the Houston Innovators Podcast. "Each one of those funds, will invest in 15 to 20 underlying private companies. So, at the end of the day, HX Venture Fund 1 will have exposure to 10 VC funds, as an example, and — by virtue of those investments — maybe 300 private companies."

The HX Venture Fund is aiming to raise between $50 million and $70 million for its first fund. Last year, HXVF made six investments, and Wallis says she expects another three to five investments in 2020. Ultimately, Wallis says, HXVF is looking to get a wide range of of firms involved — from early stage to later, growth stages — as well as a diversity in industries of focus.

Beyond the money, HXVF is opening up the discussion on a national scale, with visiting VCs and potential investors.

"We are getting a lot of interest in coastal VCs who want to invest here," Wallis says on the podcast.

Wallis, who is a co-founder of Weathergage Capital, got her MBA at Northwestern University's Kellogg School of Management, but has been in Houston for most of her career — traveling to each coast for business. Wallis shares her expertise, discussing everything from why the IPO process has slowed to what startups need to know about venture capital.

Listen to the full episode below — or wherever you get your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings